Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | How dose and regimen impact levodopa bioavailability

Joaquim Ferreira, MD, PhD, University of Lisbon, Lisbon, Portugal, discusses the long-standing use of levodopa as a standard treatment for Parkinson’s disease and highlights the ongoing gaps in knowledge about its optimal dosage and administration. Despite being the most effective and safe drug available for Parkinson’s disease management over the past 60 years, there is still much to learn about its usage. Prof. Ferreira shares recent data from a trial comparing different doses and regimens of levodopa when used in combination with a COMT inhibitor such as opicapone. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


J.J.F received grants from GlaxoSmithKline, Grunenthal, Fundação MSD (Portugal), TEVA, MSD, Allergan, Novartis, Medtronic and Angelini. Received consultancy and speaker fees and participated in advisory boards for GlaxoSmithKline, Novartis, TEVA, Lundbeck, Solvay, BIAL, Merck-Serono, Merz, Ipsen, Biogen, Acadia, Allergan, Abbvie, Sunovion Pharmaceuticals, Zambon, Affiris, Roche, ONO and SK Chemicals.